NCT01547780View on ClinicalTrials.gov

Translocator Protein and Inflammation After Traumatic Brain Injury

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 20, 2012

Primary Completion Date

September 28, 2017

Study Completion Date

September 28, 2017

Conditions
Traumatic Brain Injury (TBI)Healthy
Interventions
DRUG

[11C]PBR28 and Positron Emission Tomography (PET)

Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

Suburban Hospital

OTHER

collaborator

Uniformed Services University of the Health Sciences

FED

lead

National Institute of Mental Health (NIMH)

NIH

NCT01547780 - Translocator Protein and Inflammation After Traumatic Brain Injury | Biotech Hunter | Biotech Hunter